-2-

PC 27010

Amendments to the Claims:

1. (Once Amended) A compound of Formula (I):

wherein Z is -CHR⁹ , -C(O) , -O , - or -S -, S(O) -, -SO₂ -, N(R⁹) , -C(O)N(R⁹) , or N(R⁹)C(O) -;

l is 1 or 2:

m is 0, 1 or 2;

n is 1 or 2:

 R^1 and R^2 are each independently hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, or $(C_{3-6}$ cycloalkyl) C_{1-6} alkyl; provided that R^1 and R^2 are not both hydrogen;

R³ is hydrogen or C₁₋₆alkyl;

 R^4 -and R^5 , and R^9 are independently hydrogen, C_{1-6} alkyl or aryl C_{1-6} alkylene;

 R^6 , R^7 , and R^8 are independently hydrogen, fluoro, chloro, bromo, CF_3 , -OCF₃, -N(R^{10})₂, C_{1-6} alkyl, C_{1-6} alkoxy, heteroaryl or aryl;

each R^{10} is independently hydrogen, or $-C_{1-6}$ alkyl;

wherein any C_{1-6} alkyl, C_{1-6} alkylene, or C_{1-6} alkoxy of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , and R^{10} is optionally partially unsaturated;

wherein any heteroaryl or aryl is optionally substituted with one or two substituents independently selected from halo, -CF₃, -OCF₃, C_{1-6} alkoxy, -N(R^{10})₂, and C_{1-6} alkyl;

or a pharmaceutically acceptable salt thereof.

-3-

PC 27010

- 2. (Original) The compound of claim 1, wherein R¹ is hydrogen.
- 3. (Original) The compound of claim 1, wherein R^1 is C_{1-6} alkyl, C_{3-6} cycloalkyl, or $(C_{3-6}$ cycloalkyl) C_{1-6} alkyl.
- 4. (Original) The compound of claim 1, wherein R^1 is C_{2-6} alkyl, C_{3-6} cycloalkyl, or $(C_{3-6}$ cycloalkyl) C_{1-6} alkyl.
- 5. (Original) The compound of claim 1, wherein R¹ is C₃₋₆alkyl, C₃₋₆cycloalkyl, or (C₃₋₆cycloalkyl)C₁₋₆alkyl.
- 6. (Original) The compound of claim 1, wherein R¹ is methyl, ethyl, propyl, isopropyl, or cyclopropylmethyl.
- 7. (Original) The compound of claim 1, wherein R¹ is ethyl, propyl, isopropyl, or cyclopropylmethyl.
- 8. (Original) The compound of claim 1, wherein R¹ is propyl, isopropyl, or cyclopropylmethyl.
 - 9. (Original) The compound of claim 1, wherein R² is hydrogen.
- 10. (Original) The compound of claim 1, wherein R^2 is C_{1-6} alkyl, C_{3-6} cycloalkyl, or $(C_{3-6}$ cycloalkyl) C_{1-6} alkyl.

-4-

PC 27010

- 11. (Original) The compound of claim 1, wherein R^2 is C_{2-6} alkyl, C_{3-6} cycloalkyl, or $(C_{3-6}$ cycloalkyl) C_{1-6} alkyl.
- 12. (Original) The compound of claim 1, wherein R^2 is C_{3-6} alkyl, C_{3-6} cycloalkyl, or $(C_{3-6}$ cycloalkyl) C_{1-6} alkyl.
- 13. (Original) The compound of claim 1, wherein R² is methyl, ethyl, propyl, isopropyl, or cyclopropylmethyl.
- 14. (Original) The compound of claim 1, wherein R² is ethyl, propyl, isopropyl, or cyclopropylmethyl.
- 15. (Original) The compound of claim 1, wherein R² is propyl, isopropyl, or cyclopropylmethyl.
 - 16. (Original) The compound of claim 10, wherein R¹ is hydrogen.
- 17. (Original) The compound of claim 1, wherein R^1 is C_{2-3} alkyl and R^2 is hydrogen, or C_{2-6} alkyl.
- 18. (Original) The compound of claim 1, wherein \mathbb{R}^1 is hydrogen, or C_{2-3} alkyl; and \mathbb{R}^2 is C_{2-6} alkyl.
 - 19. (Original) The compound of claim 1, wherein R¹ is C₂₋₃alkyl and R² is C₂₋₆alkyl.
- 20. (Original) The compound of claim 1, wherein R¹ is ethyl or propyl and R² is ethyl, propyl or butyl.

-5-

PC 27010

- 21. (Original) The compound of claim 1, wherein R³ is hydrogen.
- 22. (Original) The compound of claim 1, wherein R³ is C₁₋₆alkyl.
- 23. (Once Amended) The compound of claim 2322, wherein; and R³ is methyl, ethyl, propyl, or buryl.
- 24. (Once Amended) The compound of claim 2322, wherein; and R³ is methyl or ethyl.
- 25. (Original) The compound of claim 1, wherein R⁴ and R⁵ are independently hydrogen, methyl, ethyl, propyl, butyl, 2-phenylethyl, or benzyl.
- 26. (Original) The compound of claim 25, wherein R⁴ and R⁵ are independently hydrogen, methyl, ethyl, propyl, or benzyl.
- 27. (Original) The compound of claim 25, wherein R⁴ and R⁵ are independently methyl, ethyl, or benzyl.
- 28. (Original) The compound of claim 1, wherein R^6 , R^7 , or R^8 is phenyl optionally substituted with one or two substituents independently selected from halo, -CF₃, -OCF₃, C_{1-6} alkoxy, -N(R^{10})₂, and C_{1-6} alkyl.
- 29. (Original) The compound of claim 28, wherein R⁶, R⁷, or R⁸ is phenyl optionally substituted with one or two substituents independently selected from fluoro, chloro, bromo, -CF₃, -OCF₃, C₁₋₆alkoxy and -N(R¹⁰)₂.

-6-

PC 27010

- 30. (Original) The compound of claim 28, wherein R⁶, R⁷, or R⁸ is phenyl optionally substituted with one or two substituents independently selected from fluoro, chloro, and bromo.
- 31. (Original) The compound of claim 28, wherein R⁶ is 2,4-dichlorophenyl or 2,6-difluorophenyl.
- 32. (Original) The compound of claim 28, wherein R⁷ is 2,4-dichlorophenyl or 2,6-difluorophenyl.
- 33. (Original) The compound of claim 28, wherein R⁸ is 2,4-dichlorophenyl or 2,6-difluorophenyl.
 - 34. (Canceled)
 - 35. (Canceled)
- 36. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.

37-41. (Canceled)

42. (Original) A method for treating a disease or condition in a mammal in need thereof wherein the 5-HT receptor is implicated and modulation of 5-HT function is desired comprising administering a therapeutically effective amount of a compound of claim 1 to the mammal.

-7-

PC 27010

- 43. (Original) The method of claim 42, wherein the disease is anxiety, obesity, depression, or a stress related disease.
 - 44. (Canceled)
 - 45. (Once Amended) A compound of Formula (II):

(II)

wherein Z is $-\frac{CHR^9}{\cdot}$, $-\frac{C(O)}{\cdot}$, $-\frac{O}{\cdot}$, $-\frac{S}{\cdot}$, $-\frac{S(O)}{\cdot}$, $-\frac{SO_2}{\cdot}$, $-\frac{N(R^9)}{\cdot}$, $-\frac{C(O)N(R^9)}{\cdot}$, or $-\frac{N(R^9)C(O)}{\cdot}$;

l is 1 or 2;

m is 0, 1 or 2;

n is 1 or 2:

 R^1 and R^2 are each independently hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, or $(C_{3-6}$ cycloalkyl) C_{1-6} alkyl; provided that R^1 and R^2 are not both hydrogen;

 R^3 is -C(O)-aryl, -C(O)-heteroaryl, -C(O)-C₁₋₆alkyl, -C(O)-C₁₋₆haloalkyl, -C(O)O-C₁₋₆alkyl, or -C(O)O-C₁₋₆haloalkyl, where aryl or heteroaryl is optionally substituted with one or two halo, -CF₃, -OCF₃, C₁₋₆alkoxy, -N(R^{10})₂, or -C₁₋₆alkyl;

R⁴,-and R⁵,-and R⁹ are independently hydrogen, C₁₋₆alkyl or arylC₁₋₆alkylene;

 R^6 , R^7 , and R^8 are independently hydrogen, fluoro, chloro, bromo, CF_3 , $-OCF_3$, $-N(R^{10})_2$, C_{1-6} alkyl, C_{1-6} alkoxy, heteroaryl or aryl;

each R^{10} is independently hydrogen, or -C₁₋₆alkyl;

-8-

PC 27010

wherein any C_{1-6} alkyl, C_{1-6} alkylene, or C_{1-6} alkoxy of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , and R^{10} is optionally partially unsaturated;

wherein any heteroaryl or aryl is optionally substituted with one or two substituents independently selected from halo, -CF₃, -OCF₃, C_{1-6} alkoxy, -N(R^{10})₂, and C_{1-6} alkyl.

46-47. (Canceled)